J&J
Renewed BARDA backing boosts J&J’s COVID-19 vaccine funding by $1bn
November 17, 2020Manufacturing and Production, Research and Development BARDA, COVID-19, J&J, JJ, Janssen, Vaccine
Johnson & Johnson has said that it is injecting around $1 billion of funding into its research efforts to develop …
J&J launches second global COVID-19 vaccine trial, evaluating two-dose regimen
November 16, 2020Research and Development, Sales and Marketing COVID-19, J&J, JJ, Janssen, Vaccine
Johnson & Johnson has kicked off a second global Phase 3 trial to assess the safety and efficacy of its …
J&J’s appeal shot down over $2.12m payment due to allegedly carcinogenic talc products
November 4, 2020Research and Development, Sales and Marketing J&J, JJ, baby powder, ovarian cancer, talc
Johnson & Johnson has suffered a legal defeat in its ongoing dispute with consumers over damages relating to use of …
Johnson & Johnson to contribute a further $1 billion to US opioid settlement
October 14, 2020Research and Development, Sales and Marketing J&J, JJ, opioid crisis, opioids, pharma
Johnson & Johnson will pay another $1 billion to settle lawsuits alleging it fuelled the opioid crisis in the US. …
J&J halts COVID-19 vaccine study following unidentified participant illness
October 13, 2020Manufacturing and Production, Research and Development COVID-19, J&J, JJ, Vaccine, pharma
Johnson & Johnson has announced its decision to slam the brakes on the development programme for its COVID-19 vaccine following …
Johnson & Johnson’s vaccine candidate for COVID-19 has shown efficacy in a small group of Syrian golden hamsters
September 4, 2020Medical Communications COVID-19, J&J, JJ
Johnson & Johnson’s vaccine candidate for COVID-19 has shown efficacy in a small group of Syrian golden hamsters.
Novavax and Janssen commit 90 million COVID-19 vaccine doses to UK Government with two new deals
August 14, 2020Manufacturing and Production, Medical Communications, Sales and Marketing COVID-19, J&J, JJ, Novavax, UK, pharma
The UK Government has signed a new deal with Johnson & Johnson and Novavax to secure 90 million orders of …
US to pay Johnson and Johnson $1 billion for COVID-19 vaccine
August 6, 2020Business Services COVID-19, J&J, JJ, Johnson and Johnson, coronavirus
The US will pay Johnson and Johnson more than $1 billion to create 100 million doses of COVID-19 vaccine. The …
J&J under fire from 170 nonprofits to halt baby powder sales worldwide because it contains asbestos
July 9, 2020Sales and Marketing Cancer, J&J, JJ, pharma, talc
In the latest chapter in Johnson & Johnson’s talc-related woes, the company is being pressured by group of over 170 …
Emergent forges five-year partnership to produce one billion doses of Janssen’s COVID-19 vaccine
July 7, 2020Manufacturing and Production COVID-19, Emergent, J&J, JJ, Janssen, coronavirus
As many pharma firms move to secure upscaled manufacturing capacity for their potential COVID-19 vaccines, Johnson & Johnson’s Janssen has …
Johnson & Johnson cuts price of anti-TB medicine in poorer countries
July 7, 2020Manufacturing and Production J&J, JJ, TB
Johnson & Johnson have announced that it will cut the price of its tuberculosis drug Bedaquiline, sold under the brand …
EU reportedly in talks with J&J to secure doses of its COVID-19 vaccine
June 19, 2020Medical Communications, Research and Development, Sales and Marketing COVID-19, EU, Europe, J&J, JJ, Vaccine
It has been reported that the European Union is currently negotiating a deal with pharma giant Johnson & Johnson to …
Jury orders Johnson & Johnson to pay $750 million in latest baby powder case
February 7, 2020Medical Communications J&J, JJ, Johnson & Johnson, ovarian cancer, talc, talc powder
Johnson & Johnson have been ordered to pay by a jury $750 million to four plaintiffs over the company’s baby …
Johnson & Johnson CEO testifies for the first time in Baby Powder Cancer trial
January 28, 2020Manufacturing and Production J&J, JJ, Johnson & Johnson, Talc Powder Cancer, baby powder, talc powder
Johnson & Johnson CEO Alex Gorsky faced questions around stock sales and his knowledge of asbestos in the company’s baby …
J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma
December 9, 2019Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma
Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …
